Pyruvate kinase deficiency of red cells: genes and variants
Explore variant evidence for Pyruvate kinase deficiency of red cells across 1 analyzed protein (PKLR). Linked ClinVar records include 23 pathogenic or likely pathogenic variants, 28 variants of uncertain significance and 18 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Pyruvate kinase deficiency of red cells
PKLR: Pyruvate kinase PKLR
It catalyzes the final ATP-generating step of glycolysis in red blood cells and liver. Biallelic loss-of-function variants cause pyruvate kinase deficiency, leading to chronic nonspherocytic hemolytic anemia because erythrocytes cannot maintain adequate ATP production.
23 ClinVar pathogenic / likely pathogenic and 44 uncertain variants in PKLR have source records linked to Pyruvate kinase deficiency of red cells. Association strength is not clinical gene validity.
Weakly linked (only a few uncertain records): NTRK1.
ClinVar pathogenic and likely pathogenic variants linked to Pyruvate kinase deficiency of red cells
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| PKLR R510Q | 510 | Pathogenic / likely pathogenic (★★★★) | |
| PKLR R532P | 532 | Pathogenic / likely pathogenic (★★) | |
| PKLR R504L | 504 | Pathogenic / likely pathogenic (★★) | |
| PKLR R532W | 532 | Pathogenic / likely pathogenic (★★) | |
| PKLR G275R | 275 | Pathogenic / likely pathogenic (★★) | |
| PKLR T384M | 384 | Pathogenic / likely pathogenic (★★) | |
| PKLR G111R | 111 | Pathogenic / likely pathogenic (★★) | |
| PKLR D331E | 331 | Pathogenic / likely pathogenic (★★) | |
| PKLR G341A | 341 | Pathogenic / likely pathogenic (★★) | |
| PKLR R479H | 479 | Pathogenic / likely pathogenic (★★) | |
| PKLR N393S | 393 | Pathogenic / likely pathogenic (★★) | |
| PKLR R486W | 486 | Pathogenic / likely pathogenic (★★) | |
| PKLR R504H | 504 | Pathogenic / likely pathogenic (★) | |
| PKLR G305E | 305 | Pathogenic / likely pathogenic (★) | |
| PKLR I471F | 471 | Pathogenic / likely pathogenic (★) | |
| PKLR R490L | 490 | Pathogenic / likely pathogenic (★) | |
| PKLR R498S | 498 | Pathogenic / likely pathogenic (★) | |
| PKLR R531S | 531 | Pathogenic / likely pathogenic (★) | |
| PKLR L75P | 75 | Pathogenic / likely pathogenic (★) | |
| PKLR R359P | 359 | Pathogenic / likely pathogenic | |
| PKLR Q421K | 421 | Pathogenic / likely pathogenic | |
| PKLR M356R | 356 | Pathogenic / likely pathogenic | |
| PKLR S130Y | 130 | Pathogenic / likely pathogenic |
Uncertain variants prioritized for review in Pyruvate kinase deficiency of red cells
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| PKLR R532Q | 532 | Conflicting reports (★) | +7: 3 other pathogenic changes within 3 positions; R532P at the same position is pathogenic; seen in 8.2e-06 of gnomAD DNA copies; REVEL 0.960 | |
| PKLR R504C | 504 | Conflicting reports (★) | +6: 2 other pathogenic changes within 3 positions; R504L at the same position is pathogenic; REVEL 0.974 | |
| PKLR R531C | 531 | Conflicting reports (★) | +6: 3 other pathogenic changes within 3 positions; R531S at the same position is pathogenic; seen in 1.4e-06 of gnomAD DNA copies; REVEL 0.719 |
Which prediction tools work for Pyruvate kinase deficiency of red cells
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- AlphaMissense: 100 out of 100
- MetaLR: 100 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaSVM: 100 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- REVEL: 100 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CATVariant: 98 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MutPred: 97 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- ESM1b (LLR): 94 out of 100
- CADD: 92 out of 100
- PolyPhen-2: 88 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SIFT: 83 out of 100
- phyloP: 77 out of 100
- SpliceAI: 55 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- Pangolin: 34 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Diseases related to Pyruvate kinase deficiency of red cells
- Pyruvate kinase hyperactivity, also linked to PKLR
Frequently asked questions
Which genes have records linked to Pyruvate kinase deficiency of red cells?
This view contains 1 analyzed proteins: PKLR. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 23 pathogenic or likely pathogenic variants, 28 variants of uncertain significance and 18 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 3 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 119 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center